drugset / Trial / NCT03382314

HDDO-1614 Bio Equivalence Study

NCT03382314

Phase 1 Completed 38 enrolled Hyundai Pharmaceutical Co., LTD.
RandomizedCrossoverOpen-labelOther

Summary

A randomized, open-label, single-dose, crossover study

Timeline

Start
2017-10-16
Primary completion
2017-12-21
Completion
2018-01-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bazedoxifene Other / unclassified
Comparator Cholecalciferol Other / unclassified

Indications